Search
ICSR supplementation is equivalent to human serum for CAR engineered T cell expansion
Primary human T cells were obtained from the University of Pennsylvania Human Immunology Core. T cells were activated with Dynabeads CD3/CD28 at a 3:1 bead per cell ratio in the respective media (commercially available hematopoietic medium with 5% human AB serum or 5% Immune Cell Serum Replacement [ICSR]) and transduced with CART19 lentiviral vector. Cells were expanded in T-225 flasks over the duration of the culture. T cells were counted with a Coulter Multisizer 3 and expanded until they reached near resting size. T cell expansion is represented as cumulative T cell numbers plotted over time.
Acknowledgement
We thank James L. Riley and Andrew Medvec from the University of Pennsylvania, Department of Microbiology, for their support in generating this data.
![Primary human T cells were obtained from the University of Pennsylvania Human Immunology Core. T cells were activated with Dynabeads CD3/CD28 at a 3:1 bead per cell ratio in the respective media (commercially available hematopoietic medium with 5% human AB serum or 5% Immune Cell Serum Replacement [ICSR]) and transduced with CART19 lentiviral vector. Cells were expanded in T-225 flasks over the duration of the culture. T cells were counted with a Coulter Multisizer 3 and expanded until they reached near resting size. T cell expansion is represented as cumulative T cell numbers plotted over time.<br><br><b>Acknowledgement</b><br>We thank James L. Riley and Andrew Medvec from the University of Pennsylvania, Department of Microbiology, for their support in generating this data.](http://tools.thermofisher.com/content/sfs/gallery/low/A2596101-serum-equivalency.jpg)
